OverviewSuggest Edit

Stereotaxis specializes in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. The Company's' core technologies are the Niobe ES Remote Magnetic Navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems and the Vdrive Robotic Mechanical Navigation system and consumables.
TypePublic
Founded1990
HQSt. Louis, US
Websitestereotaxis.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2018)119(+2%)
Job Openings7
Revenue (FY, 2018)$29.3 M(-5%)
Share Price (Jan 2020)$5.2

Key People/Management at Stereotaxis

Nathan Fischel

Nathan Fischel

Director
Arun Menawat

Arun Menawat

Director
Robert J. Messey

Robert J. Messey

Director
Show more

Stereotaxis Office Locations

Stereotaxis has offices in St. Louis, Xicheng Qu, Shinjuku and Wormerveer
St. Louis, US (HQ)
Cortex 1, 4320 Forest Park Ave #100
Xicheng Qu, CN
511 1 Nao Shi Kou Da Jie
Wormerveer, NL
67 Zaanweg
Show all (4)

Stereotaxis Financials and Metrics

Stereotaxis Revenue

Embed Graph
View revenue for all periods
Stereotaxis's revenue was reported to be $29.35 m in FY, 2018
USD

Revenue (Q3, 2019)

8.2m

Gross profit (Q3, 2019)

6.4m

Gross profit margin (Q3, 2019), %

77.7%

Net income (Q3, 2019)

43.7k

EBIT (Q3, 2019)

(41.2k)

Market capitalization (20-Jan-2020)

347.6m

Closing stock price (20-Jan-2020)

5.2

Cash (30-Sept-2019)

31.7m

EV

318.5m
Stereotaxis's current market capitalization is $347.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

42.0m46.6m38.0m35.0m37.7m32.2m31.1m29.3m

Revenue growth, %

(8%)8%(15%)

Cost of goods sold

12.5m14.8m11.0m8.2m10.4m7.5m10.8m5.7m

Gross profit

29.5m31.8m27.0m26.8m27.2m24.6m20.4m23.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

11.6m8.5m12.3m10.5m8.4m9.7m10.8m8.4m8.0m8.9m9.5m9.7m9.3m8.6m7.9m8.3m7.0m8.5m8.1m7.0m7.6m7.6m7.0m6.8m8.2m

Cost of goods sold

3.5m2.7m3.8m3.3m2.2m2.5m3.5m1.6m2.0m2.3m2.6m2.9m2.4m2.2m1.1m2.3m1.3m2.2m1.9m1.3m1.4m1.6m1.4m1.1m1.8m

Gross profit

8.1m5.9m8.5m7.3m6.2m7.3m7.3m6.7m6.1m6.5m6.9m6.7m6.8m6.5m6.8m6.1m5.7m6.3m6.2m5.7m6.2m5.9m5.6m5.7m6.4m

Gross profit Margin, %

70%69%69%69%74%75%68%81%75%74%72%70%74%75%86%73%82%74%76%82%82%78%80%83%78%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.0m7.8m13.8m7.3m5.6m8.5m3.7m10.8m

Accounts Receivable

11.1m11.6m7.6m6.5m6.4m1.1m4.3m5.0m

Prepaid Expenses

3.1m3.5m1.9m1.1m785.2k750.1k963.7k

Inventories

6.0m5.1m4.9m6.4m4.5m5.4m1.1m1.2m
USDY, 2019

EV/EBIT

-7.7 k x

EV/CFO

-117.9 x

Financial Leverage

1.9 x
Show all financial metrics

Stereotaxis Online and Social Media Presence

Embed Graph

Stereotaxis News and Updates

Stereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference

Conference Focuses on Role of Digital Technology in Healthcare; David Fischel Named Panelist in Robotics Session Conference Focuses on Role of Digital Technology in Healthcare; David Fischel Named Panelist in Robotics Session

Stereotaxis Reports 2019 Third Quarter Financial Results

ST. LOUIS, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019.

Stereotaxis Reports 2019 Second Quarter Financial Results

ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with t…

Stereotaxis Reports 2019 First Quarter Financial & Operational Results

ST. LOUIS, May 09, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019. In separate press releases issued concurrently with thi…

Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19

ST. LOUIS, March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-19 in L…

Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures

ST. LOUIS and CARLSBAD, Calif., March 15, 2019 /PRNewswire/ -- Stereotaxis (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully treated utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The integrated technologies ...
Show more

Stereotaxis Blogs

Dr. Ruxing Wang

"In China, we regularly perform three or more ablations per day. RMN allows us to get out of the heavy lead, focusing more on patient care in an easy, relaxed way." The post Dr. Ruxing Wang appeared first on Stereotaxis.

Dr. Rajdeep Gaitonde

“The Niobe is a highly sophisticated system allowing precision, reducing fluoroscopy time, and improving outcomes.”

Dr. Lynne Hung

Dr. Lynne Hung remembers it well. “Before Stereotaxis, we stood next to patients, manually pushing catheters and using X-ray for positioning,” she says of the EP team at Mission Hospital in Southern California. Now, with the Niobe, they are able to sit in a control room, using a joystick to control …

Dr. Karthik Ramaswamy

For some providers today, it’s business. For Dr. Karthik Ramaswamy, medicine is still a personal thing. After helping to pioneer robotic cardiac ablation at Northeast Georgia Medical Center in 2005, Dr. Ramaswamy, the selfproclaimed “number one fan of Stereotaxis,” brought his passion for the techno…

Dr. David Burkhardt

“Any job is easy if you love what you do,” says Dr. David Burkhardt. Even so, he’s worked very hard to be one of the best in his field. Dr. Burkhardt, Cardiac EP at the Texas Cardiac Arrhythmia Institute (TCAI) in Austin, TX, is sought out worldwide for his expertise in treating complicated scar-rel…

Dr. Brad Bacik

In his more than 300 remote magnetic procedures, Dr. Brad Bacik of Aria Health in Philadelphia has tackled some of the most challenging AF and VT cases. Learning from one of the best in applying RMN to cardiac ablation – Dr. Hiroshi Nakagawa from the University of Oklahoma – Dr. Bacik says he feels …
Show more

Stereotaxis Frequently Asked Questions

  • When was Stereotaxis founded?

    Stereotaxis was founded in 1990.

  • Who are Stereotaxis key executives?

    Stereotaxis's key executives are Nathan Fischel, Arun Menawat and Robert J. Messey.

  • How many employees does Stereotaxis have?

    Stereotaxis has 119 employees.

  • What is Stereotaxis revenue?

    Latest Stereotaxis annual revenue is $29.3 m.

  • What is Stereotaxis revenue per employee?

    Latest Stereotaxis revenue per employee is $246.6 k.

  • Who are Stereotaxis competitors?

    Competitors of Stereotaxis include Trilliant Surgical, Intuitive Surgical and TransEnterix.

  • Where is Stereotaxis headquarters?

    Stereotaxis headquarters is located at Cortex 1, 4320 Forest Park Ave #100, St. Louis.

  • Where are Stereotaxis offices?

    Stereotaxis has offices in St. Louis, Xicheng Qu, Shinjuku and Wormerveer.

  • How many offices does Stereotaxis have?

    Stereotaxis has 4 offices.